BiotechTube

Pancreatic Enzyme

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Short Bowel Syndrome

Conditions

Short Bowel Syndrome

Trial Timeline

Mar 24, 2017 → Feb 1, 2019

NCT ID
NCT03097029

About Pancreatic Enzyme

Pancreatic Enzyme is a phase 2 stage product being developed by AbbVie for Short Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03097029. Target conditions include Short Bowel Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03097029Phase 2Completed

Competing Products

20 competing products in Short Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
somatropin + leuprorelinEli LillyPhase 3
77
Growth HormoneEli LillyApproved
85
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3
77
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)MerckPhase 1
33
Saizen® + Saizen®MerckPhase 3
77
r-metHuLeptinAmgenPhase 1
32
Somapacitan + Norditropin®Novo NordiskPhase 2
51
Somatotropin growth hormone recombinant humanPfizerApproved
84
Genotropin (somatropin)PfizerApproved
84
Genotropin + GenotropinPfizerPhase 3
76
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved
84
GenotropinPfizerPhase 2/3
64
glepaglutideZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
ZP1848Zealand PharmaPhase 2
49
glepaglutide + PlaceboZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Glepaglutide 10 mgZealand PharmaPhase 3
74
GlepaglutideZealand PharmaPhase 3
74
Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved
82

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85